Tier 2 — strong
Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial
BMC endocrine disorders
2023
23(1):190
Bibliography
- PubMed
- PMID 37679692
- PubMed Central
- PMC10483788
- Funding
- Funded by Siksha O Anusandhan; the authors reported no extramural funding.
- Competing interests
- The authors declared no known competing financial interests or personal relationships.
Study snapshot
| Design | Double-blind placebo-controlled randomized pilot |
|---|---|
| Model | Human participants; see population |
| Sample | 34 adults with prediabetes |
| Intervention | HIMABERB berberine 500 mg three times/day versus placebo |
| Duration | 12 weeks |
| Endpoints | Fasting and postload glucose; HbA1c and insulin sensitivity; Lipid profile and tolerability |
What the study showed, in plain terms
Key findings
What this study can and cannot tell us
Citation network
Articles citing this research paper
Biohack Blueprint analyses that reference this study in their evidence base.
- Berberine for Blood Sugar: Diabetes, Insulin Resistance and HbA1cReview berberine for blood sugar, HbA1c, insulin resistance and prediabetes. Compare controlled trials, real effect sizes, monitoring and safety.Read analysis
- Berberine Side Effects: Digestive Symptoms and Long-Term SafetyUnderstand berberine side effects, digestive complaints, glucose concerns, heart-rhythm reports, long-term safety limits and when to seek medical help.Read analysis
- Berberine Dosage: Study Doses, Capsule Strengths and SafetyCompare berberine study doses for glucose, weight and lipids. Understand 500 mg capsules, formulation differences, dose limits, duration and safety.Read analysis
Editorial review
Reviewed by the Biohack Blueprint research team
Last verified
